

Avizakimab

Cat. No.:	HY-P99451
CAS No.:	2229685-51-0
Target:	Interleukin Related
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Avizakimab (BOS161721) is a humanized IgG1 monoclonal antibody that targets interleukin-21 ^[1] .
In Vitro	Avizakimab (BOS161721) prevents IL-21 binding to the IL-21 receptor (IL-21R) and inhibits bioactivity ^[1] . Avizakimab inhibits the downstream signaling, plasma cell differentiation, and natural killer cell activation induced by IL-21 and suppressed antibody responses to keyhole limpet hemocyanin (KLH) antigen ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Hussaini A, et al. A Double-Blind, Phase I, Single Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of BOS161721 in Healthy Subjects. Clin Transl Sci. 2020 Mar;13(2):337-344.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA